Cancer immunotherapy

Cancer immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system. Some cancer immunotherapies consist of antibodies that bind to, and inhibit the function of, proteins expressed by cancer cells. Other cancer immunotherapies include vaccines and T cell infusions.

Featured

Latest Research and Reviews

  • Reviews |

    An estimated 20% of all patients with cancer will develop brain metastases, with the majority of brain metastases occurring in those with lung and breast cancer and melanoma. This Primer describes the mechanisms by which cancer cells migrate to the brain and the key advances necessary to improve the prognosis for patients with brain metastases.

    • Achal Singh Achrol
    • , Robert C. Rennert
    • , Carey Anders
    • , Riccardo Soffietti
    • , Manmeet S. Ahluwalia
    • , Lakshmi Nayak
    • , Solange Peters
    • , Nils D. Arvold
    • , Griffith R. Harsh
    • , Patricia S. Steeg
    •  & Steven D. Chang
  • Research | | open

    Targeting the immune-stimulatory receptor 4-1BB has only yielded modest benefit in cancer treatment. In this study, the authors show that CD73 expression on effector T cells sustained by TGF-β drives tumor resistance to anti-4-1BB therapy and therefore TGF- β blockade can be used to overcome such resistance.

    • Siqi Chen
    • , Jie Fan
    • , Minghui Zhang
    • , Lei Qin
    • , Donye Dominguez
    • , Alan Long
    • , Gaoxiang Wang
    • , Renqiang Ma
    • , Huabin Li
    • , Yi Zhang
    • , Deyu Fang
    • , Jeffrey Sosman
    •  & Bin Zhang
  • Research |

    A hyper-stable de novo protein mimic of interleukin-2 computationally designed to not interact with a regulatory T-cell specific receptor subunit has improved therapeutic activity in mouse models of melanoma and colon cancer.

    • Daniel-Adriano Silva
    • , Shawn Yu
    • , Umut Y. Ulge
    • , Jamie B. Spangler
    • , Kevin M. Jude
    • , Carlos Labão-Almeida
    • , Lestat R. Ali
    • , Alfredo Quijano-Rubio
    • , Mikel Ruterbusch
    • , Isabel Leung
    • , Tamara Biary
    • , Stephanie J. Crowley
    • , Enrique Marcos
    • , Carl D. Walkey
    • , Brian D. Weitzner
    • , Fátima Pardo-Avila
    • , Javier Castellanos
    • , Lauren Carter
    • , Lance Stewart
    • , Stanley R. Riddell
    • , Marion Pepper
    • , Gonçalo J. L. Bernardes
    • , Michael Dougan
    • , K. Christopher Garcia
    •  & David Baker
    Nature 565, 186-191
  • Reviews |

    The rapid progress in cancer immuno therapy has highlighted the need for new delivery technologies. In this article, Langer, Mitchell and colleagues discuss how recent developments in drug delivery could enable new cancer immunotherapies and improve on existing ones, and examine the current delivery obstacles.

    • Rachel S. Riley
    • , Carl H. June
    • , Robert Langer
    •  & Michael J. Mitchell

News and Comment